NEW YORK – Danaher executives said Wednesday that the firm expects the effects from the volume-based procurement program in China and anticipated lower respiratory testing volumes will have an impact ...

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.

While Roche saw a 1 percent decline in full-year 2024 diagnostics sales year over year, the base business within the division rose 8 percent. Overall, Roche reported ...

For Q1 2025, Danaher said it expects core revenues will decline in the low-single-digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.

The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

The finalized local coverage determinations were set to go into effect on Feb. 23 but have been pushed back two months.

Last week, readers were most interested in a story about Roche gaining FDA clearance and CLIA waiver for its STI point-of-care test.

The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess ...